Observing the progression of CADASIL over time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor individuals diagnosed with CADASIL, a genetic disorder affecting small blood vessels, to understand its impact on blood vessel health over time. Participants, including both CADASIL patients and healthy volunteers, will undergo a series of evaluations and tests over a nine-year period, including blood and urine sample collection, cognitive assessments, and imaging studies. The study will focus on the pathogenesis and clinical variability of CADASIL, utilizing biospecimens for molecular research. The goal is to gather comprehensive data to better understand the disease's progression and its effects on mental and physical health.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

Eligibility for this study may be determined based on information collected under other NHLBI-approved protocols, outside records and patient report.

In order to be eligible to participate in this study, an individual must meet criteria 1 \& 2 and either criteria 3 or 4:

1. Stated willingness to comply with all study procedures and availability for the duration of the study.
2. Male or female, aged 18 to 100 years (inclusive).
3. Established diagnosis of CADASIL or NOTCH3 mutations, as determined by genetic testing.
4. Healthy controls.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Pregnancy at time of consent.
2. Subjects who lack capacity to consent and don't have a legally authorized representative.
3. Subjects who decline to provide samples for blood and/or tissue studies.
4. Subjects who do not speak English.
5. Subjects whose scans or examinations show unexpected brain conditions (outside of CADASIL) which would interfere with interpretation of testing.
6. Subjects unable to undergo an MRI scan or subjects meeting the following criteria:

   * Subjects who have internal non-MRI compatible metals (i.e., cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain or on blood vessels, cochlear implants, artificial heart valves or metal fragments in the eye) as these rendering an MRI unsafe
   * Subjects with ferromagnetic dental bridges or crowns (exclusion only for 7.0T)
   * Subjects unable to remain supine for the expected length of the MRI (i.e., up to 1 hour)
   * Subjects with uncontrolled head movements
   * Subjects who are claustrophobic for the expected length of the MRI (i.e., up to 1 hour) and claustrophobia cannot be controlled with anti-anxiety medication.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Elisa A Ferrante Brenlla, Ph.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Ruth C Brower, R.N.
• Email: ruth.brower@nih.gov
• Phone: (301) 443-6036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Petrelintide for weight loss in people with overweight/obesity and heart disease

  This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

  Recruiting at 3 sites Phase 3 Hoffmann-La Roche · Anniston, Alabama and 2 other locations · NCT07843472

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Sleep and arterial function in hypertensive patients with poor sleep quality

  This trial tests whether using cognitive-behavioural therapy for insomnia can improve artery health and well-being in adults with high blood pressure and poor sleep.

  Recruiting Unidade Local de Saúde do Alto Ave, EPE · Guimarães, Braga District · NCT07789535

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Improving Care for underserved older Black patients with cardiovascular and other chronic conditions

  This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07748858

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.